In the clinical screening of prostate cancer, the use of the prostate-specific antigen (PSA) is the predominant means towards the diagnosis of prostate cancer, although this approach is limited due to the potential of the PSA levels to also be elevated in cases where there is benign prostate hyperplasia and prostatic inflammation [16,17,18,19]. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.